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Abstract
Introduction: The Epstein Barr Virus (EBV) has been associated with the
autoimmune disease, Systemic Lupus Erythematosus (SLE). EBV nuclear antigen-I
(EBNA-1) is the major nuclear protein of EBV. We previously generated an IgG
monoclonal antibody (MAb) to EBNA-1, 3D4, and demonstrated that it cross-
reacts with double stranded DNA (dsDNA) and binds the 148 amino acid viral
binding site (VBS) in the carboxyl region of EBNA-1. The aim of the present study
was to characterize another antibody to EBNA-1 that cross-reacts with dsDNA,
compare its immunoglobulin genes to 3D4, and finely map the epitope in EBNA-1
that is recognized by these cross-reactive antibodies.
Methods: We generated an IgM MAb to EBNA-1, 16D2, from EBNA-1 injected
mice and demonstrated by ELISA that it cross-reacts with dsDNA and binds the
148 amino acid VBS.We sequenced the variable heavy and light chain genes of 3D4
and 16D2 and compared V gene usage. To more finely map the epitope in EBNA-1
recognized by these MAbs, we examined their binding by ELISA to 15 overlapping
peptides spanning the 148 amino acid domain.
Results: Sequence analysis revealed that 3D4 and 16D2 utilize different VH and VL
genes but identical JH and Jk regions with minimal junctional diversity. This
accounts for similarities in their CDR3 regions and may explain their similar dual
binding specificity. Epitope mapping revealed 3D4 and 16D2 bind the same
peptide in the VBS. Based on the crystal structure of EBNA-1, we observed that this
peptide resides at the base of an exposed proline rich loop in EBNA-1.
Conclusion: We have demonstrated that two MAbs that bind EBNA-1 and cross-
react with dsDNA, recognize the same peptide in the VBS. This peptide may serve
as a mimetope for dsDNA and may be of diagnostic and therapeutic value in SLE.
Introduction
Autoimmune diseases such as Systemic Lupus Erythematosus
(SLE) are caused by a constellation of genetic, environmental,
and hormonal factors. Environmental triggers include
pathogens that may elicit an autoimmune response as a
consequence of molecular mimicry. Some viruses that have
been associated with SLE are herpes zoster, cytomegalovirus
(CMV), humanendogenous retroviruses and theEpsteinBarr
Virus (EBV) [1–5]. Specific proteins and peptides derived
from these viruses are thought to mimic nuclear self antigens
and thereby elicit antibodies that cross-react with these
autoantigens.
The association of EBV with SLE originally stems from
observations that the prevalence of EBV infection is higher in
SLE adolescents than age matched controls, that EBV
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infection sometimes precedes SLE, and that EBV DNA and
EBV viral load are higher in SLE patients than healthy
individuals [2, 6–10]. In addition, SLE patients have elevated
expression of EBV mRNA’s and a higher frequency of
antibodies to EBV early antigens, capsid antigens, and latent
membrane proteins than controls [11–14]. Further evidence
linking EBV to SLE is based on studies demonstrating that
antibodies to the Epstein Barr virus nuclear antigen 1
(EBNA-1), the major nuclear protein in EBV which is
expressed in all EBV infected cells, cross-react with the
splicesomal ribonucleoproteins, Sm B/B0, SmD, nRNPs, and
Ro. Antibodies to Sm are observed in approximately 25%
and antibodies to Ro in approximately 50% of lupus
patients [2, 15]. Sabbatini et al. [16] observed that a G-R
repeat region in Sm D is homologous to a region in EBNA-1
and demonstrated that SLE sera that recognized a G-R
peptide derived from SmD, also recognized the G-R peptide
derived from EBNA-1. Mice immunized with this EBNA-1
peptide, developed antibodies to Sm D as well as to the
immunizing peptide.
James and Harley [17] identified a proline rich peptide in
EBNA-1 (PPPGRRP) that is homologous to a proline rich
peptide in Sm B/B0 (PPPGMRPP). They showed that sera
from lupus patients but not controls bound the EBNA-1
derived peptide and that rabbits and mice immunized with
PPPGRRP from EBNA-1 developed antibodies that cross-
reacted with Sm B/B0 as well as nRNPs [18, 19]. In a
subsequent study, McClain et al. [20] observed that another
peptide in EBNA-1 elicited a cross-reactive response to a
peptide in the ribonucleoprotein, Ro. Interestingly, no
primary sequence homology was observed between the
EBNA-1 and Ro peptides but both were noted to have
similarly high isoelectric points and to share structural
similarities. Together these studies reveal how a viral antigen
can act as a molecular mimic for an autoantigen and
illustrate the role of molecular mimicry in the etiology of
lupus autoantibodies.
Antibodies to double stranded DNA (dsDNA) are the
hallmark of SLE and are found in 50–80% of SLE patients.
Although dsDNA is a target of anti-dsDNA antibodies, it is
not known whether dsDNA is the eliciting antigen.
Screening of phage peptide libraries has identified peptides
derived from autoantigens that serve as molecular mimics
for dsDNA [21–23]. Antibodies to nRNPs have been shown
to cross-react with dsDNA [24]. Studies in the laboratory of
John Harley have shown that some animals immunized with
PPPGRPP developed antibodies to dsDNA, but they
hypothesized that this was due to epitope spreading rather
than cross-reactivity [18–20].
We previously demonstrated that mice injected with an
EBNA-1 expression vector or the EBNA-1 protein, devel-
oped antibodies to dsDNA [25, 26]. To determine the basis
of this anti-dsDNA response, we generated IgG monoclonal
antibodies (MAbs) to EBNA-1 from EBNA-1 injected mice
and tested them for cross-reactivity with dsDNA. We
identified an IgG MAb designated 3D4 and demonstrated
that it cross-reacts with dsDNA. We showed that this MAb
recognizes a 148 amino acid domain in the carboxyl region
of EBNA-1 [25].
We now describe a recently generated IgM MAb to
EBNA-1 (16D2) that also cross-reacts with dsDNA.
Although this MAb utilizes different heavy and light chain
genes than 3D4, it recognizes the same carboxyl domain in
EBNA-1. The present study was undertaken to more finely
map the peptide epitope in EBNA-1 that can serve as a
peptide mimic for dsDNA. By screening an overlapping
peptide library derived from this 148 amino acid domain, we
have identified a peptide target of both 3D4 and 16D2.
Understanding how a peptide derived from a pathogen can
serve as a molecular mimic for dsDNA may have important
implications for diagnostic and therapeutic strategies in SLE.
Materials and Methods
Purification of rEBNA-1 lacking the Gly-Ala repeat
Recombinant EBNA-1 (rEBNA-1) lacking most of the G-A
repeat was purified from a baculovirus expression vector
kindly provided by Dr. Lori Frappier (University of Toronto,
Toronto, Canada), as previously described [25, 27]. The
rEBNA-1 protein contains a 6x His tag at the amino termini,
which allowed for its isolation on Ni2þ-NTA beads.
Mouse immunization and somatic cell fusion
BALB/c mice were injected intraperitoneally with 50mg of
rEBNA-1 in complete Freund’s adjuvant (CFA) 1:1(v/v) and
boosted at weeks 3, 7, and 12 with 25mg of rEBNA-1 in
incomplete Freund’s adjuvant (IFA) 1:1(v/v). Mice were
serially bled and sera examined by ELISA for antibodies to
EBNA-1 and dsDNA. Three days after the last boost, mouse
splenocytes were harvested and fused to NSO cells according
to Iliev et al. [28]. Hybridoma, supernatants were tested by
ELISA for IgM and IgG antibodies to EBNA-1 and dsDNA.
Hybridomas producing MAbs to EBNA-1 that cross-react
with dsDNA or non dsDNA binding anti-EBNA-1 MAbs
were subcloned two times at limiting dilution. The MAbs
were grown in serum freemedia and IgGMAbs were purified
on protein G sepharose columns.
Isolation of truncated recombinant EBNA-1
proteins
PCR fragments encoding the amino and carboxyl regions of
rEBNA-1 were previously cloned into a pET28a Escherichia
coli expression vector carrying an N-terminal His tag, as
previously described [25]. The amino fragment (LS8)
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encompassing aa 1–404 and lacking the G-A repeat and the
carboxyl fragment (LS9) encompassing aa 410–641 were
isolated from IPTG induced E. coli lysates and purified on
Ni2þ-NTA beads according to Yadav et al. [25].
Plasmids (pET15b) carrying an N-terminal His tag and
expressing the following truncated EBNA-1 proteins;
EBNA452-641, EBNA459-619, EBNA459-607, were a generous
gift from Dr. Lori Frappier [29]. These fragments were
expressed in E. coli strain BL21 (DE3) and isolated from cell-
lysates on Ni2þ-NTA beads [25].
Crithidia luciliae assay
Ready to use Crithidia slides (Antibodies Inc., Davis, CA)
were immunostained with MAb, 16D2 at 10mg/ml. Slides
were incubated in a moist chamber for 30min at room
temperature, washed extensively in PBS and then immu-
nostained with a 1:1000 dilution of goat anti-mouse IgM
FITC (Southern Biotech, Birmingham, AL) for 30min at
room temperature. Slides were washed again in PBS and then
were examined by fluorescence microscopy using a Nikon
Eclipse microscope, TE 2000-S at 40 magnification.
Ig heavy and light chain cDNA synthesis and
sequencing
Total RNA was isolated from hybridomas producing MAbs
3D4 or 16D2, using Trizol reagent (Life Technologies,
Thermo Fisher Scientific, Waltham, MA) according to the
manufacturers protocol. First strand cDNA was prepared by
RT-PCR using 3.5mg of RNA, 50 ng of random hexamers
and 200U of superscript III RT (Invitrogen, Life Technology,
Carlsbad, CA, USA) according to the manufacturers
protocol.
Two rounds of PCR amplification were performed for the Ig
heavy and light chain genes using 2.0ml cDNA (for the first
PCR) or 3.0ml of first PCR product (for the second PCR),
250mMof eachdNTP, 0.5mMof each primer, and 1.5UofHot
Star Taq polymerase (Qiagen, Germantown, MD) in a total
reaction mixture of 50ml. The first round of PCR was
performed at 948C for 15min followed by 50 cycles of 948C for
30 sec, 568C (IgH) or 508C (Igk) for 30 sec, 728C for 55 sec, and
a final extension at 728C for 10min according to Tiller
et al. [30]. Primers used for the first PCRwere 50mVHE (GGGA
ATTCGAGGTGCAGCTGCAGGAGTCTGG) and 30Cg1 outer
(GGAAGGTGT GCACACCGCTGGAC) for the g1 heavy
chain gene, 50mVHE and 30Cm outer (AGGGGGCTCTCG
CAGGAGACGAGG) for the m heavy chain gene, and 50 mVk
(GAYATTGTGMTSACMCARWCTMCA) and 30 Ck outer
(ACTGAGGCACCT CCAGATGTT) for the kappa light chain
gene. Semi-nested second round PCR was performed at
948C for 15 min, followed by 50 cycles of 948C for 30 sec,
608C(for IgH)or 458C(for Igk) for 30 sec, 728C for 45 sec and a
final extension at 728C for 10min [30]. Primers used for the
second PCR were 50 mVHE and 30Cg1 inner (GCTCAGG
GAAATAGGCCTTGAC) for theg1 heavy chain, 50 mVHEand
30Cm inner (AGGGGGAAGACATTTGGGAAGGAC) for them
heavy chain genes and 50mVk and 30 Ck inner (TGGGAA
GATGGATACAGTT) for the kappa light chain gene (Christian
Busse, personal communication). PCR products from the 2nd
PCR were analyzed on a 2% agarose gel and sequenced
(Macrogen, Rockville, MD). Germline heavy and light chain
genes were identified by IgBLAST.
ELISAs
Direct ELISAs for binding to dsDNA, EBNA-1, LPS, Sm, and
Proteinase 3
ELISAs to examine direct antibody binding to EBNA-1,
dsDNA, truncated fragments of EBNA-1, LPS, Sm, and
Proteinase 3 were as previously described [25, 26, 31]. Either
goat anti-mouse IgM or goat anti-mouse IgG conjugated to
alkaline phosphatase (AP) (Southern Biotech) were used as
secondary antibodies to detect binding of 16D2 or 3D4,
respectively, to antigen coated plates. Isotype ELISAs to
determine whether additional IgG MAbs were of the IgG1,
IgG2a, IgG2b, or IgG3 subclass were performed as previously
described [25].
Anti-peptide ELISAs
Fifteen peptides containing a five amino acid overlap,
derived from a 148 amino acid region in the viral
dimerization/binding domain in the carboxyl region of
EBNA, were synthesized and biotinylated at the amino
termini by LifeTein LLC (Hillsborough, NJ). Purity of all
peptides was greater than 80%. Costar ELISA plates
(Corning Inc., Corning, NY) were coated overnight at
48C with a 1:1000 dilution of streptavidin in PBS (Southern
Biotech). The next day, plates were blocked in PBS, 1% BSA,
for 2 h at room temperature. Plates were then incubated with
100mg/ml of biotinylated-peptide (50ml per well) for 1 h at
378C followed by six washes in PBS, 0.05% tween 20. Plates
were next incubated for 1 h at 378C with 5mg/ml of 3D4 or
10mg/ml of 16D2 diluted in PBS, 0.1% BSA. Plates were
washed and then incubated with a 1:1000 dilution of goat
anti-mouse IgG-AP or goat anti-mouse IgM-AP to detect
3D4 or 16D2 binding, respectively. Plates were developed
with 4-nitrophenyl phosphate disodium hexahydrate as
substrate and read at 405 nm on a Titertek Multiscan ELISA
reader. To compare the binding of 16D2 or 3D4 to
biotinylated EBNA-1 versus biotinylated PFM-15 peptide,
ELISAs were performed as described above except that
following the coating with streptavidin, plates were
incubated with mole equivalents of biotinylated PFM-15
or biotinylated EBNA-1. EBNA-1 was biotinylated using
Mapping a viral peptide mimic for dsDNA P. Yadav et al.
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EZ-Link Sulfo-NHS-Biotinylation Kit (Thermo Scientific,
Rockford IL). Following biotinylation, biotinylated EBNA-1
(B-EBNA-1) was applied to a Zeba Desalt Spin Column
(Thermo Scientific) and then dialyzed against PBS to remove
excess biotin.
Peptide inhibition ELISAs
For peptide inhibition of MAb binding to dsDNA, 3D4
(2.5mg/ml) and 16D2 (5mg/ml) were pre-incubated for
1 h at 378C with increasing concentrations of peptide
PFM-15 or GC-15 (concentrations of peptide ranging from
0.1mg/ml to 100mg/ml) and then transferred to pre-
blocked dsDNA coated Immulon-2 plates (Dynatech
Laboratories Inc., Chantilly, VA). Plates were then
incubated for 2 h at 378C, washed, and then incubated
with 1:1000 dilution of goat anti-mouse IgG-AP or goat
anti-mouse IgM-AP to detect 3D4 or 16D2 binding,
respectively. Plates were developed with substrate as
described above. MAbs were used at a concentration
resulting in 50% maximal binding to dsDNA.
For peptide inhibition of MAb binding to EBNA-1, 3D4
(0.05mg/ml) and 16D2 (5mg/ml) were incubated with
increasing concentrations of peptide PFM-15 or GC-15,
ranging from 0.1mg/ml to 1mg/ml and then transferred to
pre-blocked EBNA-1 coated Costar plates. Plates were then
incubated for 1 h at 378C, and the remainder of the ELISA
was performed as described above. MAbs were used at a
concentration resulting in 50% optimal binding to EBNA-1.
Results
Wepreviously demonstrated that somemice immunizedwith
EBNA-1 developed antibodies to EBNA-1 that cross-reacted
with dsDNA. We generated anti-EBNA-1 MAbs from one of
these mice and observed that 71% of the anti-EBNA-1 MAbs
cross-reactedwith dsDNA [25]. Pragya et al. [25] described an
IgG MAb, designated 3D4, that binds with high affinity to
EBNA-1 and cross-reacts with dsDNA (Fig. 1A and B).
Epitope mapping revealed that 3D4 recognizes a 148 amino
acid fragment in the carboxyl region of EBNA-1 [25].
Characterization of an IgM anti-EBNA-1 MAb
(16D2) that cross-reacts with dsDNA
In the present study, we characterized an IgM MAb to
EBNA-1, designated 16D2, that was generated from somatic
cell fusion following injection of a mouse with recombinant
EBNA-1 protein lacking the glycine alanine repeat region, as
previously described [25]. We demonstrated by ELISA that
16D2 binds EBNA-1 and cross-reacts with dsDNA,
(Fig. 2A and B). Further confirmation of cross-reactivity
with dsDNA was demonstrated by binding of 16D2 to the
kinetoplast, a dsDNA containing organelle, of the protozoa,
Crithidia luciliae (Fig. 2C). Since IgM antibodies are part of
an early immune response and are often polyreactive, we
examined 16D2 for its polyreactivity. 16D2 was tested by
ELISA for binding to a panel of antigens frequently
recognized by polyreactive antibodies (Fig. 2E). 16D2 was
not observed to be polyreactive as it did not bind BSA, LPS,
Sm, or Proteinase 3 (PR3), a target autoantigen inWegener’s
Granulomatosis.
16D2 recognizes an epitope in the carboxyl region
of EBNA-1
Since 16D2, was observed to bind EBNA-1 and cross-react
with dsDNA, we wondered whether it would recognize the
same epitope in EBNA-1 as 3D4. We therefore examined
16D2 for reactivity with the amino and/or carboxyl regions
of EBNA-1. Recombinant EBNA-1 proteins representing the
amino and carboxyl regions of EBNA-1 were purified in our
laboratory from E. coli plasmid expression vectors as
described by Yadav et al. [25] and were coated on ELISA
plates. The amino fragment designated LS8 contains amino
acids 1–404 (lacking the G-A repeat), whereas, the carboxyl
fragment designated LS9 contains amino acids 410–641
(Fig. 3A). 3D4 was previously shown to bind LS9 but not
LS8. In the present study, we demonstrated that 16D2 also
binds LS9 but not LS8 (Fig. 3B). We next tested 16D2 for
binding to three truncated recombinant protein fragments
derived from the carboxyl region of EBNA-1; EBNA452-641,
Figure 1. IgG antibody to EBNA-1 cross-reacts with dsDNA. IgGMAb, 3D4 binds strongly to EBNA-1 (A) and cross-reacts with dsDNA (B) as determined
by ELISA. ELISAs are representative of three experiments. ELISA values were obtained in triplicate. Error bars indicate standard deviations of triplicates.
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EBNA459-619, and EBNA459-607 (Fig. 3C). These fragments
were purified from recombinant E. coli expression plasmids
kindly provided to us by Dr. Lori Frapier (University of
Toronto). 16D2 was shown to bind strongly to all 3
fragments (Fig. 3D). The smallest fragment, which is 148
amino acids (aa) long (EBNA459-607), corresponds to the
viral dimerization/DNA binding site (VBS) of EBNA-1. 3D4
was previously shown to bind strongly to this fragment as
well [25].
Comparison of the relative binding of 3D4 and
16D2 to EBNA-1
Comparison of the relative binding of 16D2 and 3D4 to
EBNA-1 was demonstrated by ELISA. Both antibodies
were serially diluted and incubated on the same EBNA-1
coated ELISA plate and goat anti-mouse kappa-AP was
added as secondary antibody (Fig. 4). In two out of two
trials, the binding of 3D4 to EBNA-1, as measured by OD
values was relatively higher than the binding of 16D2 to
EBNA-1, within the range of 0.04–1mg/ml of antibody.
This suggests, but does not prove that 3D4 binds more
strongly to EBNA-1 than 16D2. However, other factors
can account for these observations and accurate mea-
surement of antibody binding strength and affinity will
require precise kinetic binding assays such as surface
plasmon resonance.
Sequence analysis of the VH and VL genes of 3D4
and 16D2
The variable heavy (VH) and light chain (VL) genes of 3D4
and 16D2 were sequenced to determine their identity.
Sequences were analyzed using Ig BLAST (NCBI database) to
determine the closest germline genes of origin. Both
antibodies were found to utilize different VH and VL genes
but the same JH and Jk gene segments (Tables 1 and 2). 3D4
was found to have 99% homology to the VH germline gene
VH7183.14 and 98.3% homology to the VL germline gene,
bb1. 16D2 was found to have the closest homology (95.8%)
to the germline gene, VH J558.16 and 100% homology to the
germline VL gene, 8–30. 3D4 has three mutations in its VH
region (Supplementary Fig. S1) and five mutations in its VL
region (Supplementary Fig. S2). 16D2 has 12mutations in its
VH region, six of which are silent (Supplementary Fig. S3).
The 16D2VL is identical to the germline gene 8–30
(Supplementary Fig. S4). Interestingly, 16D2 and 3D4
utilize the same JH2 segment in their VH regions and the
same JK1 in their VL regions. Furthermore, the D-J joints of
both MAbs lack junctional diversity as the carboxy terminal
Figure 2. 16D2 cross-reacts with dsDNA. 16D2 was tested by ELISA for binding to EBNA-1 (A) and dsDNA (B). Binding to dsDNA was conﬁrmed by
immunostaining of the kinetoplast of Crithidia luciliae (C). Immunostaining of an isotype control MAb is shown in D (D). 16D2 was tested by ELISA for
reactivity with a panel of antigens; Sm, LPS, BSA, and proteinase 3 (PR3) (E). Results are representative of three experiments. ELISA values were obtained
in triplicate. Error bars indicate standard deviations of triplicate values.
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YFDYW amino acids of both CDR3s are JH2 germline
encoded (Table 1). The carboxy terminal PWTF amino acids
in the Vk CDR3s of 3D4 and 16D2 are both Jk2 germline
encoded. 16D2 was noted to contain three positively charged
arginine residues in its CDR3VH region, while 3D4 has one.
Arginine residues are frequently observed among anti-
dsDNA antibodies [32, 33]. The lengths of the VH CDR3
regions in 3D4 and 16D2 (33 and 39 amino acids,
respectively) are slightly longer than normal a characteristic
of many autoreactive and polyreactive antibodies [34, 35].
The lengths of the VL CDR3 regions of 3D4 and 16D2 (30
amino acids) are average. The length of the CDR3 regions
were determined by counting the amino acid residues after
the conserved cysteine at the end of FR3 to the conserved
tryptophan-glycine in all mouse JH segments or the
conserved phenylalanine-glycine in all Jk segments [30].
Mapping the peptide epitope in EBNA-1 that is
recognized by 3D4 and 16D2
To more finely map the epitope/s recognized by 3D4 and
16D2, fifteen overlapping, linear oligopeptides spanning the
entire 148 amino acid VBS domain in the carboxyl region of
EBNA-1 (EBNA459-607) were synthesized and biotinylated at
the amino terminal end (LifeTein, South Plainfield, NJ). All
peptides were either 15 or 12 amino acids long with a 4–6
amino acid overlap (Table 3). Biotinylated peptides were
attached to streptavidin coated ELISA plates and the binding
of 3D4 and 16D2 to these peptides was examined. Both 3D4
and 16D2 bound stronger to peptide PFM-15 than to any of
the other overlapping peptides (Fig. 5A and B). However,
16D2 bound much more strongly to PFM-15 than 3D4.
When equimolar concentrations of B-EBNA-1 and
B-PFM-15 were attached to streptavidin, 16D2 bound
significantly more to B-PFM-15 than to B-EBNA-1 while
3D4 bound significantly less to B-PFM-15 than to B-EBNA-1
(Fig. 5A and B, insets). These results suggest that PFM-15 is
the optimal target of 16D2 but not of 3D4. 3D4 likely
recognizes a conformational epitope that is partially
comprised of PFM-15. 3D4 displayed weak binding to
several other peptides including RG-15, (aa 459–473), DS-15
(aa 499–513), and VE-15 (aa 559–573). 16D2 also displayed
weak binding to VE-15. RG-15 and DS-15 show no
homology to PFM-15, however VE-15 has some homology
Figure 3. 16D2 binds to an epitope in the carboxyl region of EBNA-1. (A) Open reading frame map of EBNA-1 showing the amino (LS8) and carboxyl
(LS9) region. (B) 16D2 was tested by ELISA for binding to LS8 and LS9 and shown to bind LS9 only. (C) Schematic of three truncated recombinant
fragments of LS9 expressed in and puriﬁed from E. coli. (D) 16D2 was tested by ELISA for binding to the truncated fragments, aa 452–641, aa 459–619,
and aa 459–607 and compared to the binding to LS9 (aa 410–641). ELISAs are representative of two experiments. ELISA values were obtained in
triplicate. Error bars indicate standard deviations of triplicates.
Figure 4. Comparison of the binding of 3D4 and 16D2 to EBNA-1. The
binding of 16D2 and 3D4 to EBNA-1were compared by ELISA. Goat anti-
mouse kappa-AP was used as secondary antibody to detect the binding
of 16D2 (an IgM MAb) and 3D4 (an IgG MAb) in the same assay. Results
represent the average of two experiments. Standard deviation is
indicated by error bars.
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and shares a 5 amino acid overlap (VCYFM) at its 50 endwith
the 30termini of PFM-15 (aa 549–563) (Table 3).
The VBS has been crystallized in the laboratory of Dr. Lori
Frappier in both the DNA bound and unbound forms
[36, 37]. Based on the crystal structure, we mapped peptide
PFM-15 to an exposed proline loop in the VBS domain at
amino acids 549–563 [37]. The proline loop consists of a
repeating P-G motif followed by several 30 terminal
hydrophobic amino acids. To determine which amino acids
in PFM-15 are critical for the binding of 16D2 and 3D4, two
additional overlapping peptides, GC-15 (GPGPQPGPLRE-
SIVC) (aa 546–560) and GL-15 (GPLRESIVCYFMVFL) (aa
552–566) were synthesized and tested by ELISA for 3D4 and
16D2 binding (Fig. 5C, D, and E). GC-15, GL-15, and PFM-
15 have a common core of amino acids GPLRESIVC. GC-15
shares three additional upstream amino acids (PQP) with
PFM-15, while GL-15 shares 3 additional downstream
amino acids (YFM) with PFM-15 (Fig. 5C). Interestingly,
neither 3D4 nor 16D2 bound GC-15, yet both bound GL-15,
suggesting that amino acids YFM are critical for binding.
3D4 did not show a significant difference in binding GL-15
compared to PFM-15, while 16D2 displayed significantly
higher binding to PFM-15 than to GL-15 (Fig. 5D and E).
The only difference between these two peptides is that GL-15
lacks PQP at its 50 terminus and contains VFL at its 30
terminus. PQP may be important for optimal binding of
16D2 while VFL may weaken it.
We next examined whether PFM-15 could competitively
inhibit binding of 16D2 and 3D4 to EBNA-1 (Fig. 6A and B)
and dsDNA (Fig. 6C and D). A fixed concentration of 16D2
and 3D4 that resulted in 50% maximal binding to EBNA-1
was incubated with increasing concentrations of peptide. At
100mg/ml of peptide, PFM-15 inhibited 16D2 from binding
to EBNA-1 by almost 70% (Fig. 6A) but inhibited 3D4 from
binding to EBNA-1 by only 10% (Fig. 6B). However, when
the concentration of PFM-15 was increased tenfold to1mg/
ml it also induced almost 70% inhibition of 3D4 binding to
EBNA-1. This inhibition was specific as 1mg/ml of a control
peptide, GC-15 had no affect on 3D4 binding to EBNA-1
(B). These results demonstrate that PFM-15 can competi-
tively inhibit binding of both antibodies to EBNA-1 but
that16D2 binds more strongly to PFM-15 than 3D4. The
observation that a high concentration of PFM-15 is required
to inhibit binding of 3D4 to EBNA-1, further supports the
hypothesis that this linear peptide is part of a conformational
epitope that is optimally recognized by 3D4.
To examine whether PFM-15 could inhibit binding to
dsDNA, fixed concentrations of 16D2 and 3D4 that resulted
in 50% maximal binding to dsDNA were incubated with
increasing concentrations of peptide. At 100mg/ml, PFM-15
inhibited binding of both 16D2 and 3D4 to dsDNA by
approximately 60% (Fig. 6C and D) suggesting that this
peptide can mimic dsDNA and therefore partially block
antibody binding to dsDNA.
Characterization of four MAbs to EBNA-1 that do
not cross-react with dsDNA
In the present study, we also generated four MAbs (14E10,
4B8, 4F6, and 2F8) to EBNA-1 that do not cross-react with
dsDNA. We were interested in determining the region in
EBNA-1 that these antibodies bind relative to the cross-
reactive antibodies. The isotype used by all four of these
antibodies was shown to be IgG1; the same isotype used by
3D4 (Fig. 7A). Binding to EBNA-1 was examined at a range
of concentrations, by ELISA and depicted in Figure 7B.
14E10 and 4B8 displayed similar binding to EBNA-1 as 3D4,
while 4F6 and 2F8 displayed weaker binding. Binding to
Table 2. VL gene analysis of 3D4 and 16D2
Light Chain
MAb Class GermlineVK JK CDR3 length CDR3 aa # mut.
3D4 k bb1 JK1 30 SQTTHVPWTF 5
16D2 k 8-30 JK1 30 QQYYSYPWTF 0
Germline encoded stretches of amino acid (aa) homology are underlined. # mut; number of mutations.
Table 1. VH gene analysis of 3D4 and 16D2
Heavy Chain
MAb Class GermlineVH D JH CDR3 length CDR3 aa # mut.
3D4 g VH7183.14 NA JH2 33 ARPPPFYFDYW 3
16D2 m J558.16 D1-201 JH2 39 ARILRLRQYFDYW 12
NA, not available. Stretches of germline encoded amino acid (aa) homology are underlined. # mut; number of mutations.
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dsDNA was also examined and depicted in Figure 7C. 4B8,
4F6, and 2F8 displayed negligible binding to dsDNA at a
concentration of 12.5mg/ml, while 14E10 displayed a low but
slightly higher level of binding to dsDNA than the other
three MAbs (Fig. 7C). We next examined the binding of
these MAbs at a concentration of 1.25mg/ml to the amino
and carboxyl regions of EBNA-1. MAbs 4B8, 4F6, and 2F8
bound to the carboxyl region of EBNA-1 but not the amino
region (Fig. 7D). However, 14E10 failed to bind to either the
amino or carboxyl regions (Fig. 7D) suggesting that it
recognizes a conformational epitope in EBNA-1 formed by
the folding of the amino and carboxyl regions, or that it
binds to an epitope that spans the junction of these two
regions. We subsequently examined the binding of MAbs,
2F8, 4F6, and 4B8 to two of the truncated fragments
(Fig. 3A and C) within the VBS in the carboxyl region of
EBNA-1; EBNA452-641 and EBNA459-607 (Fig. 7E). All three of
these MAbs failed to bind to both truncated fragments
although they recognized the complete carboxyl region
(aa 410–641). Failure to bind to the larger of these two
fragments (EBNA452-641) suggests that amino acids upstream
of the VBS, and 50 of aa 452, are critical for recognition by
Table 3. Overlapping peptide sequences spanning the 148 amino acid
VBS domain (EBNA459-607) of EBNA-1
Peptide Amino acid sequence Amino acid position
RG-15 RKKGGWFGKHRGQGG 459–473
RE-15 RGQGGSNPKFENIAE 469–483
EH-15 ENIAEGLRALLARSH 479–493
LW-15 LARSHVERTTDEGTW 489–503
DS-15 DEGTWVAGVFVYGGS 499–513
VG-15 VYGGSKTSLYNLRRG 509–523
NL-15 NLRRGTALAIPQCRL 519–533
PM-15 PQCRLTPLSRLPFGM 529–543
LP-15 LPFGMAPGPGPQPGP 539–553
PFM-15 PQPGPLRESIVCYFM 549–563
VE-15 VCYFMVFLQTHIFAE 559–573
HV-15 HIFAEVLKDAIKDLV 569–583
II-15 IKDLVMTKPAPTCNI 579–593
TD-12 TCNIRVTVCSFD 590–601
TP-12 TVCSFDDGVDLP 596–607
Regions of amino amino acid overlap are underlined. Peptide recognized
by 3D4 and 16D2 is shaded in gray.
Figure 5. Peptide mapping. 3D4 (A) and 16D2 (B) were tested by ELISA for binding to peptides spanning the entire 148 amino acid VBS region. Insets
compare binding of 3D4 and 16D2 to EBNA-1 and PFM-15. (C) Comparison of amino acid sequence of homologous peptides GC-15, PFM-15, and
GL-15. Common core region of all three peptides is underlined. Regions of overlap between GC-15 and PFM-15 and between PFM-15 and GL-15 are
bolded. 3D4 (D) and 16D2 (E) were examined by ELISA for binding to GC-15, GL-15, and PFM-15. 3D4was used at a concentration of 5mg/ml and 16D2
at 10mg/ml for all above ELISAs. ELISAs are representative of two experiments. ELISA values were obtained in triplicate. Error bars represent standard
deviations of triplicates. Standard t test (2 tail, type 1) performed to compare signiﬁcance of binding to EBNA-1 versus PFM in A and B and to compare
signiﬁcance of binding to PFM-15 versus GL-15 in D and E.
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these antibodies. It is interesting that only the cross-reactive
antibodies target an epitope that resides within the VBS.
Discussion
In an earlier study, we identified an IgG antibody to EBNA-1,
3D4, which cross-reacts with dsDNA. In the present study we
identified another antibody to EBNA-1, 16D2, of the IgM
isotype, which also cross-reacts with dsDNA. We have
compared the binding properties, sequences, and epitope
specificity of both antibodies to determine if there are
similarities that could help explain the structural properties
that confer dual specificity.
Fine mapping of the target epitopes in EBNA-1 for 3D4
and 16D2, revealed that they recognize an epitope localized
to a 148 amino acid domain in the carboxyl region of
EBNA-1 that coincides with the VBS (aa 459–607). Epitope
mapping using overlapping peptides that span the entire148
amino acid domain revealed that both 3D4 and 16D2 bind
more strongly to peptide, PFM-15 (PQPGPLRESIVCYFM)
than any other linear peptide in this region. The binding of
these MAbs to PFM-15 is not due to charge interactions as
PFM-15 is hydrophobic and has a net charge of zero.
Inhibition assays revealed that 10-fold more PFM-15 was
required to inhibit 3D4 compared to 16D2 binding EBNA-1.
Furthermore, 3D4 bound equally well to PFM-15 and the
overlapping peptide, GL-15, while 16D2 displayed signifi-
cantly less binding to GL-15 than PFM-15 (Fig. 6). These
results suggest that the epitopes targeted by the two
antibodies share some homology but are not identical.
The linear peptide PFM-15 appears to be the optimal target
epitope of 16D2 while 3D4 may prefer a structural epitope
containing PFM-15.
EBNA-1 exists as a homodimer in latently infected cells.
The VBS contains a core domain (aa 504–604) which
mediates this dimerization [38]. The VBS domain also binds
viral dsDNA recognition sites in the EBV genome and it
plays a role in the replication and mitotic segregation of the
EBV episomes. Analysis of the crystallized structures of the
VBS has enabled us tomap the PFM-15 peptide (aa 549–563)
to an exposed proline loop in the core domain which
projects from the EBNA-1 dimer [36, 37]. The proline loop
has a proline rich tip (aa 545–549) and a 50 arm (aa 538–544)
that forms hydrogen bonds with the 30 arm (aa 550–559), to
stabilize the structure [37]. PFM-15 maps to the 30 arm of
this loop. Based on these known structures, we hypothesize
Figure 6. Peptide inhibition of MAbs binding to EBNA-1 and dsDNA. 1D2 (5mg/ml) and 3D4 (0.05mg/ml) were incubated with increasing
concentrations of peptides PFM-15 or GC-15 and examined by ELISA for binding to EBNA-1 (A and B, respectively). 1D2 (5mg/ml) and 3D4 (2.5mg/ml)
were incubated with increasing concentrations of peptides PFM-15 or GC-15 and examined by ELISA for binding dsDNA (C and D, respectively). ELISAs
are representative of two experiments. ELISA values were obtained in triplicate. Error bars represent standard deviations of triplicate values.
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that 3D4 optimally recognizes a conformational epitope that
contains the linear sequence of PFM-15 as well as non-
contiguous amino acids in the loop that form hydrogen
bonds with amino acids in PFM-15.
The observation that PFM-15 could inhibit binding of
both 3D4 and 16D2 to dsDNA suggests that this peptide can
serve as a peptidemimetope for dsDNA at least at highmolar
concentrations. However, it is not yet clear from our amino
acid sequence analyses and known structural data why 3D4
and 16D2 also recognize DNA and what aspects of PFM-15
serve as the dsDNA mimic. The proline loop of EBNA-1 has
some structural flexibility and it is thought to undergo subtle
structural changes when EBNA-1 binds dsDNA [39].
Therefore, there may be some structure in the loop in the
region of the PFM-15 peptide, which enables it to mimic
DNA. It is interesting to note that the four MAbs that we
examined in this study, which bind to EBNA-1 but do not
cross-react with dsDNA, recognize an epitope that lies
outside of the proline loop. We have also examined other
peptide mimetopes of dsDNA described in the literature, to
determine if there is any similarity to PFM-15. In particular,
we examined three peptides obtained from random phage
display libraries, DWEYSVWLSN, ASPVTARVLWKASHV,
and RLTSSLRYNP [22, 40, 41]. There does not seem to be
any sequence homology that can explain this shared
property. Future studies will determine whether PFM-15
alone can elicit an anti-dsDNA response or whether it needs
to be part of a proline loop structure to elicit that response.
The sequence analysis of the variable regions of 3D4 and
16D2 reveal differences and similarities that may help
explain their shared dual binding properties. 3D4 and
16D2 utilize different VH and VL genes indicating that
more than one anti-EBNA-1 antibody can cross-react with
dsDNA. 3D4 utilizes a gene from the VH7183 family and
16D2 utilizes a gene from the VHJ558 family. Members of
these two gene families are frequently observed among
polyreactive antibodies that arise in the early immune
response and among anti-dsDNA autoantibodies [33,
42–45]. IgM antibodies that bind dsDNA are often
germline encoded and are polyreactive. Although, the
variable light chain gene of 16D2 is germline encoded, its
variable heavy chain gene is mutated. It is unclear whether
16D2’s autoreactivity is germline encoded or a conse-
quence of somatic mutation. Future studies will address
Figure 7. MAbs that bind to the carboxyl region of EBNA-1 but do not cross-react with dsDNA, recognize a different epitope than the cross-reactive
antibodies. (A) The IgG isotype of the non-cross-reactive MAbs 2F8, 14E10, 4F6, and 4B8 were determined by ELISA. (B) The non cross-reactive MAbs,
were tested by ELISA at a range of concentrations, for binding to EBNA-1. 3D4 was used as the reference standard. MAbs were tested by ELISA for
binding to dsDNA (C), to the amino and carboxyl regions of EBNA-1 (D) and to two truncated carboxyl fragments; aa 452–641 and aa 459–607 (E). MAb
concentrations used were 12.5mg/ml in (C) and 1.25mg/ml in (D) and (E). ELISAs are representative of two experiments. ELISA values were obtained in
triplicate. Error bars represent the standard deviations of triplicates.
P. Yadav et al. Mapping a viral peptide mimic for dsDNA
© 2016 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 371
this by reverting the mutations in the CDR regions to
germline and testing whether these antibodies still
recognize dsDNA. 16D2 does not appear to be poly-
reactive, as it does not bind to LPS or the autoantigens Sm
and PR3, frequently considered to be targets of poly-
reactive antibodies. However, it is unknown whether 16D2
is derived from a polyreactive precursor. Interestingly,
both 3D4 and 16D2 use the same JH and JK regions and
lack junctional diversity at the D-J joint. They share a
stretch of germline encoded amino acids at the carboxyl
ends of their CDR3 regions. These may be important
contact residues with the antigen. Moreover, both 3D4 and
16D2 contain arginine residues and phenylalanine and
tyrosine residues in their VH CDR3 regions and these basic
and aromatic amino acids appear to be conserved in
proteins that bind dsDNA [32, 33, 46]. In addition, the
CDR3 regions in the VH of 3D4 and 16D2 are slightly
longer than normal (33 and 39 amino acids, respectively), a
characteristic of many autoantibodies [34, 35].
While EBNA-1 has long been associated with SLE, most
people who get infected with EBV do not develop lupus. This
may be because healthy individuals who are exposed to EBV
may preferentially develop antibodies to parts of EBNA-1
that do not elicit cross-reactivity, as observed with the non
cross-reactive MAbs that were generated in this study.
Studies have shown that SLE patients have an altered
humoral immune response to epitopes in EBNA-1 relative to
healthy individuals [47–49]. SLE patients have been
observed to preferentially have antibodies to epitopes in
the amino and carboxyl regions of EBNA-1 while healthy
individuals have antibodies to the G-A repeat region. The
EBNA-1 protein that we injected into mice in this study did
not have a G-A region, therefore the mice were forced to
make an immune response to other regions of EBNA-1.
Antibodies to EBNA-1 that cross-react with dsDNA may be
more likely to arise in genetically susceptible individuals who
have particular MHC haplotypes.
It is interesting to speculate that other pathogens besides
EBV may have proteins containing peptides homologous to
PFM-15 that can elicit anti-dsDNA antibodies and therefore
serve as a peptide mimetope of dsDNA. Protein BLAST was
used to search for pathogen proteins containing peptides
with homology to a stretch of amino acids in PFM-15. Of
particular interest were proteins that contain the YFM amino
acid motif present at the 50 terminus of PFM-15. The
presence of this motif appears to be critical for recognition
by 3D4 and 16D2 since both MAbs failed to bind GC-15,
which shares a common peptide core with PFM-15 but lacks
YFM. The protein BLAST search identified a transporter
protein derived from the bacteria Lachnospiraceae bacte-
rium A2, which has 100% homology with seven contiguous
amino acids in PFM-15 (SIVCYFM) (see Table 3). Lachno-
spiracea belongs to the Clostridia class and is a part of the
normal gut microbiota in mice and humans. A recent study
demonstrated that young, female lupus prone mice have a
significantly increased level of Lachnospiracea relative to age
matched healthy controls [50]. In addition, Lachnospiracea
was observed to be overrepresented in female mice, which
are associated with an earlier onset of SLE and more severe
lupus like symptoms. These results suggest that gut micro-
biota may be a predisposing trigger for SLE and peptides
derived from gut pathogens may lead to autoantibody
production as a consequence of molecular mimicry.
In summary, this study describes an IgM MAb to
EBNA-1 that cross-reacts with dsDNA and compares it to a
previously identified IgG MAb that binds EBNA-1 and
cross-reacts with dsDNA. Epitope mapping of EBNA-1,
using both these MAbs, identified a target peptide that lies
at the base of the proline loop in the viral binding site of
EBNA-1. This peptide may serve as a mimetope for
dsDNA. Future studies will determine whether this peptide
can elicit an anti-dsDNA response when injected into mice.
If so, this will have important implications for treatment
strategies aimed at preventing this peptide sequence from
eliciting an autoimmune response following EBV infection
or blocking cross-reactive antibodies from binding to
target autoantigens.
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Figure S1. Variable heavy chain (VH) nucleic acid and amino
acid sequences of 3D4 and comparison to most homo-
logousVH germline gene as determined by IgBLAST (NCBI
database).
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Figure S2. Variable light chain (VL) nucleic acid and amino
acid sequences of 3D4 and comparison to most homo-
logousVL germline gene as determined by IgBLAST (NCBI
database).
Figure S3. Variable heavy chain (VH) nucleic acid and amino
acid sequences of 16D2 and comparison to most
homologousVH germline gene as determined by IgBLAST
(NCBI database).
Figure S4. Variable heavy chain (VL) nucleic acid and amino
acid sequences of 16D2 and comparison to most homo-
logousVL germline gene as determined by IgBLAST (NCBI
database).
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